Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

NCT07644312 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

High Grade Glioma
Diffuse Intrinsic Pontine Glioma
WHO Grade 3 Glioma
WHO Grade 4 Glioma
Replication Repair Deficient

Interventions

DRUG: Opdualag

Sponsor

Nationwide Children's Hospital

Collaborators

[object Object]